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Lymphatic and Immune Cell Cross-Talk Regulates 
Cardiac Recovery After Experimental Myocardial 
Infarction
Mahmoud Houssari, Anais Dumesnil, Virginie Tardif, Riikka Kivelä, Nathalie Pizzinat, Ines Boukhalfa, David Godefroy, Damien 
Schapman, Karthik A. Hemanthakumar, Mathilde Bizou, Jean-Paul Henry, Sylvanie Renet, Gaetan Riou, Julie Rondeaux, Youssef 
Anouar, Sahil Adriouch, Sylvain Fraineau, Kari Alitalo, Vincent Richard, Paul Mulder, Ebba Brakenhielm
OBJECTIVE: Lymphatics play an essential pathophysiological role in promoting fluid and immune cell tissue clearance. Conversely, immune 
cells may influence lymphatic function and remodeling. Recently, cardiac lymphangiogenesis has been proposed as a therapeutic target to 
prevent heart failure after myocardial infarction (MI). We investigated the effects of gene therapy to modulate cardiac lymphangiogenesis 
post-MI in rodents. Second, we determined the impact of cardiac-infiltrating T cells on lymphatic remodeling in the heart.
APPROACH AND RESULTS: Comparing adenoviral versus adeno-associated viral gene delivery in mice, we found that only sustained 
VEGF (vascular endothelial growth factor)-CC156S therapy, achieved by adeno-associated viral vectors, increased cardiac 
lymphangiogenesis, and led to reduced cardiac inflammation and dysfunction by 3 weeks post-MI. Conversely, inhibition of 
VEGF-C/-D signaling, through adeno-associated viral delivery of soluble VEGFR3 (vascular endothelial growth factor receptor 
3), limited infarct lymphangiogenesis. Unexpectedly, this treatment improved cardiac function post-MI in both mice and rats, linked 
to reduced infarct thinning due to acute suppression of T-cell infiltration. Finally, using pharmacological, genetic, and antibody-
mediated prevention of cardiac T-cell recruitment in mice, we discovered that both CD4+ and CD8+ T cells potently suppress, in 
part through interferon-γ, cardiac lymphangiogenesis post-MI.
CONCLUSIONS: We show that resolution of cardiac inflammation after MI may be accelerated by therapeutic lymphangiogenesis 
based on adeno-associated viral gene delivery of VEGF-CC156S. Conversely, our work uncovers a major negative role of cardiac-
recruited T cells on lymphatic remodeling. Our results give new insight into the interconnection between immune cells and 
lymphatics in orchestration of cardiac repair after injury.
VISUAL OVERVIEW: An online visual overview is available for this article.
Key Words:  heart failure ◼ inflammation ◼ interferon ◼ lymphangiogenesis ◼ macrophages
The lymphatic vasculature is essential for maintenance of interstitial fluid homeostasis and for fine-tuning of immune responses by regulating immune cell, cyto-
kine, and antigen tissue clearance.1,2 Additionally, lymphatics 
ensure the uptake of dietary lipids in chylomicrons as well 
as reverse cholesterol transport from tissues to the liver.3 
Edema or increases in osmotic pressure lead to stimulation of 
lymphatic remodeling (lymphangiogenesis), in part via mac-
rophage-driven VEGF (vascular endothelial growth factor)-
C production,4 which acts to restore tissue fluid balance. In 
See accompanying editorial on page 1611 
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contrast, the interplay between lymphatic vessels and the 
immune system is more complex: although lymphatic func-
tion is reduced by many proinflammatory mediators,5,6 dif-
ferent immune cell populations impact lymphatic remodeling 
exerting either stimulatory or inhibitory effects on lymphatic 
endothelial cell growth and survival.7,8 Conversely, tissue 
clearance of immune cells depends on active lymphatic 
expression of chemokines to selectively recruit and drain 
different immune cell populations.9,10 Promisingly, whereas 
therapeutic lymphangiogenesis has been shown to resolve 
chronic inflammation, including innate immune responses in 
many organs,11,12 treatment with lymphangiogenic inhibitors 
limits adaptive immune responses and reduces graft rejec-
tion following organ transplantation.13,14
The cardiac immune response to ischemic injury is 
characterized by sequential waves of infiltrating immune 
cells, including not only neutrophils, monocytes/macro-
phages, and dendritic cells (DCs) but also B and T lym-
phocytes. Together these cells orchestrate the removal of 
dead cardiomyocytes, participate in granulation tissue for-
mation required for stabilization and maturation of the scar, 
and regulate the subsequent cardiac repair and inflamma-
tion-resolution phase by secreting proangiogenic, prosur-
vival, and anti-inflammatory mediators.15,16 However, this 
immune cell infiltration represents a double-edged sword 
in that chronic inflammation in the heart, brought on by 
inefficient resolution of the inflammatory response, aggra-
vates cardiac dysfunction by inducing coronary endothelial 
dysfunction and deleterious cardiac remodeling, including 
cardiomyocyte hypertrophy and interstitial fibrosis, leading 
to development of chronic heart failure.17 Improved resolu-
tion of cardiac inflammation thus represents a therapeutic 
goal in many cardiovascular diseases.
The adult heart is invested with a lymphatic network 
dense over the ventricles and sparser over the atria.18 Dif-
ferent from other lymphatic beds, the cardiac precollector 
lymphatics are essentially devoid of smooth muscle cells, 
as surrounding cardiomyocytes ensure lymphatic propul-
sion towards cardiac lymph nodes (Figure I and Movie I 
in the Data Supplement). Cardiac lymphatic remodeling 
occurs in many cardiovascular diseases characterized by 
edema and inflammation,19 including in patients with isch-
emic heart disease or terminal heart failure.20,21 Indeed, 
myocardial infarction (MI) leads to lymphatic remodeling in 
both infarct and viable infarct border zone in humans, pigs, 
rats, and mice.21–26 We previously showed that stimulation 
of cardiac lymphangiogenesis post-MI in rats, using tar-
geted intramyocardial delivery of VEGFR3 (vascular endo-
thelial growth factor receptor 3)-selective recombinant rat 
VEGF-CC152S protein, accelerated resorption of chronic 
myocardial edema and inflammation, reduced deleterious 
cardiac remodeling, and improved cardiac function.26 Here, 
we investigated the impact of gene therapy to modulate 
cardiac lymphangiogenesis post-MI in rodents. Second, 
we assessed the role of cardiac-infiltrating T lymphocytes 
in lymphatic remodeling post-MI with the aim to unravel 
the interplay between the immune system and the lym-
phatic vasculature during cardiac repair.
MATERIALS AND METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Experimental Models and Therapeutic Agents
We investigated cardiac lymphatic remodeling in 20 to 22 g 
wild-type C57Bl/6J mice (Janvier Laboratories, France), in 20 
to 22 g C57Bl/6 mice deficient for MHC (major histocompat-
ibility complex) II (MHCIIΔ/Δ as a result of disruption of the IAβ 
gene) kindly provided by Dr J.P. van Meerwijk,27 and in 200 
to 220 g Wistar rats (RccHan:WIST from Harlan/Envigo) fol-
lowing MI induced by permanent coronary artery ligation.28,29 
Only female mice were used in our studies due to their superior 
Nonstandard Abbreviations and Acronyms
AAV adeno-associated virus
DCs dendritic cells
IFN interferon
IL interleukin
INF interferon
LV left ventricle
MI myocardial infarction
Pdpn podoplanin
S1P sphingosine-1-phosphate
sVEGFR3 soluble VEGF receptor 3
VEGF vascular endothelial growth factor
Highlights
• Therapeutic lymphangiogenesis in the heart 
requires prolonged VEGF (vascular endothelial 
growth factor)-C expression as achieved by adeno-
associated virus but not adenoviral gene therapy or 
systemic protein therapy.
• Therapeutic lymphangiogenesis accelerates resolu-
tion of cardiac inflammation post-MI, with reduction 
of both T-cell and proinflammatory macrophage lev-
els in the viable left ventricle, resulting in improved 
cardiac function.
• Treatment with a VEGF-C/VEGF-D trap (solu-
ble VEGFR3) acutely limits T-cell recruitment to 
the infarct, leading to delayed scar remodeling 
and reduced cardiac dysfunction postmyocardial 
infarction.
• Cardiac-infiltrating T cells, both CD4+ and CD8+ 
subpopulations, exert deleterious effects on cardiac 
lymphatics postmyocardial infarction, in part through 
interferon-γ.
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survival rates post-MI, and only male rats were used as female 
rats display more rapid left ventricular (LV) dilation.30 Modulation 
of cardiac lymphangiogenesis was performed using either sys-
temic growth factor therapy with recombinant human VEGF-
CC156S protein (RnD system) as described,
25 or using viral 
gene vectors encoding hVEGF-CC156S (human VEGF-CC156S) 
or sVEGFR3 (soluble VEGFR3)-IgG construct.29,31,32 Briefly, 
protein therapy consisted of repeated (day 0, 2, 3, 4, and 6 
post-MI) intraperitoneal injections of 2 µg/mouse (0.1 µg/g) 
of rhVEGF-CC156S (recombinant human VEGF-C mutant selec-
tive for VEGFR3) or physiological saline in controls,25 adeno-
viral therapy consisted of a single intraperitoneal injection on 
day 0 of adenoviral-5 vector (5×108 viral particles) encoding 
hVEGF-CC156S or lacZ as a control, and adeno-associated viral 
(AAV) gene delivery consisted of a single intraperitoneal injec-
tion 7 days before MI of AAV-9 vector (1×1011 viral particles) 
encoding hVEGF-CC156S, sVEGFR3, or scrambled sequence as 
a control.33
Cardiac Functional, Histological, and Cellular 
Analyses
LV function was evaluated by echocardiography,28 and cardiac 
hypertrophy-to-LV dilatation index was calculated as the ratio 
of diastolic LV wall thickness to LV diastolic diameter. Cardiac 
sections were analyzed by histology and immunohistochemis-
try to determine infarct size, lymphatic and blood vessel densi-
ties and sizes, and immune cell infiltration levels (macrophages 
and T cells) as determined using Fiji.34 Cardiac whole mount-
staining was performed26 followed by a modified iDISCO+ 
clearing protocol35 for imaging by lightsheet (ultramicroscope 
II, LaVision BioTec) and confocal laser scanning (Leica SP8, 
×25) microscopy. For details see Data Supplement.
Flow-Cytometry
Cells isolated from blood and hearts of mice were analyzed by 
flow cytometry.36,37 For details, see Data Supplement. Results 
are expressed as % of parent population or as cells per mL 
blood or per mg cardiac tissue. Flow cytometric analyses were 
performed on an LSRFortessa (BD Biosciences) and analyzed 
with FlowJo software (TreeStar, Inc, San Carlos, CA).
Prevention of T-Cell Recruitment
Fingolimod (1 mg/kg, FTY-720, Sigma-Aldrich) intraperitoneal 
pharmacological treatment was initiated immediately after MI 
in mice with repeated injections on days 1 and 2 post-MI to 
prevent cardiac T-cell recruitment acutely post-MI. MI controls 
received physiological saline. Cardiac functional and cellular 
analyses were performed as described above. For depletion 
of specific T-cell populations or cytokines, InVivoMab antibod-
ies were administered by repeated intraperitoneal injections 
on day 0 and 3 post-MI in mice according to the manufac-
turer’s instructions (BIOXCELL, NH). For details, see Data 
Supplement.
Study Approval
Animal experiments performed in this study were approved by the 
regional ethics review board in line with E.U, French and Finnish 
legislation (01181.01 / APAFIS [French Animal Experiment 
Ethical Commission] No. 8157-2016121311094625-
v5 Normandy; B315557, Toulouse ENVT [École Nationale 
Vétérinaire de Toulouse]; ESAVI/6718/04.10.03/2012, 
Helsinki). A total of 250 C57Bl/6J female mice, 20 MHCIIΔ/Δ 
and matched wild-type C57Bl/6 female mice, and 33 male 
Wistar rats surviving coronary ligation or sham-operation were 
included in this study.
Statistics
Data are presented as mean±SEM. Comparisons were per-
formed to determine (1) impact of pathology (healthy versus MI 
controls); (2) effect of treatment (treated versus MI controls). 
Statistical analyses for comparisons of 2 independent groups 
were performed using either Student 2-tailed t test for groups 
with normal distribution or alternatively by Mann Whitney U test 
for samples where normality could not be ascertained based on 
D’Agostino and Pearson omnibus normality test. For compari-
sons of ≥3 groups, either 1-way ANOVA followed by Bonferroni 
posthoc (for parameters with n>7 with normal distribution) or 
alternatively Kruskal-Wallis nonparametric analysis followed by 
Dunn posthoc multiple comparison (for parameters with n<8, 
or with n>7 but with nongaussian distribution) were performed. 
Finally, longitudinal echocardiography studies in rats were ana-
lyzed by paired 2-way ANOVA followed by Bonferroni posthoc. 
Outlier samples were identified as an individual value exceed-
ing group mean±4SD in groups with n≧7. All analyses were 
performed using GraphPad Prism software.
RESULTS
Sustained VEGF-C Delivery Is Required for 
Therapeutic Lymphangiogenesis
We previously showed that cardiac lymphatic remodeling 
after MI in rats included expansion of lymphatic capillar-
ies accompanied by precollector slimming and rarefac-
tion of open lymphatic vessels, used as a proxy of cardiac 
precollectors, both in the infarct and in the viable LV wall, 
leading to poor lymphatic transport capacity during the 
first months post-MI.26 To stimulate cardiac lymphan-
giogenesis post-MI previous studies have used protein 
therapy with VEGFR3-selective VEGF-C, either by intra-
myocardial injection, coupled to biopolymers for spatio-
temporally controlled growth factor release, in rats,26 or 
by intraperitoneal repeated injections of VEGF-CC156S 
protein in mice.25,38
We set out to compare the efficacy of systemic intra-
peritoneal protein therapy versus gene therapy with either 
adenoviral or AAV vectors to deliver VEGFR3-selective 
human VEGF-CC156S
31,32 with the aim to stimulate cardiac 
lymphangiogenesis following MI induced by permanent 
coronary artery ligation in mice. Importantly, we confirmed 
that VEGFR3 expression was essentially restricted to lym-
phatic vessels, and not blood vessels, both in healthy and 
post-MI mouse hearts (Figure IIA in the Data Supplement). 
Control MI mice were injected with saline, adenoviral-lacZ, 
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or noncoding scrambled sequence AAV control vectors, 
respectively. First, we found that intraperitoneal delivery of 
recombinant human VEGF-CC156S protein failed to increase 
circulating VEGF-C levels in mice (Figure IIIA in the Data 
Supplement) and did not increase cardiac lymphangiogen-
esis (Figure IIIB through IIID in the Data Supplement). Sec-
ond, we found that adenoviral gene delivery led to a potent, 
but transient, increase in VEGF-C plasma levels (Figure 
IVA in the Data Supplement), in line with the expected anti-
adenoviral immune response that rapidly eliminates trans-
duced cells. Such transient elevation of circulating VEGF-C 
levels was not sufficient to stimulate lymphatic expansion. 
Indeed, cardiac lymphatic proliferation and densities were 
not increased in adenoviral-VEGF-CC156S–treated mice, as 
compared to adenoviral-lacz MI controls (Figure IVB and 
IVC in the Data Supplement). In contrast, AAV–VEGF-CC156S 
gene therapy induced a potent and sustained increase in 
plasma levels (Figure IVA in the Data Supplement), as well 
as elevated and prolonged cardiac expression of hVEGF-
CC156S (Figure 1A, Figure IVD in the Data Supplement). 
This resulted in a 3-fold increase in lymphatic endothelial 
proliferation rates and lymphatic densities already by 7 
days post-MI, as compared to AAV-scrambled sequence 
MI controls (Figure IVB, IVC, and IVE in the Data Supple-
ment). Surprisingly, despite persistently elevated circulat-
ing and cardiac hVEGF-C levels in the AAV–VEGF-CC156S 
group, cardiac lymphatic proliferation (Figure 1B), but not 
density (Figure 1C), in the viable LV returned to baseline by 
21 days post-MI, indicating that factors other than VEGF-C 
bioavailability contribute to cardiac lymphatic expansion. For 
our subsequent studies, we thus focused on the AAV gene 
delivery approach to determine the functional impact of car-
diac lymphangiogenesis post-MI.
AAV–VEGF-CC156S Gene Delivery Prevents 
Cardiac Lymphatic Rarefaction Post-MI in Mice
In AAV-MI control mice, following initial destruction of 
lymphatics in the infarct zone (Figure 1E, Figure 2B) 
and rarefaction of lymphatic vessels in the viable LV 
bordering the infarct (Figure 1C through E), the subse-
quent endogenous lymphangiogenic response appeared 
weaker than in rats. Indeed, VEGF-C expression was not 
increased in the viable LV at either 7 days (Figure IVD in 
the Data Supplement) or 21 days post-MI (Figure 1A). 
In contrast, in the infarct, VEGF-C–expressing macro-
phages were observed at 7 days (Figure IVD in the Data 
Supplement). Accordingly, lymphatic proliferation only 
tended to increase in the infarct (Figure 2A) and not in 
the viable LV (Figure 1B). Similar as in rats, there was 
severe rarefaction and slimming of open lymphatics in 
the viable LV (Figure 1D, Figure VA through VD in the 
Data Supplement) and in the infarct (Figure 2B), and loss 
of button-like junctions in lymphatic capillaries, together 
suggestive of lymphatic transport dysfunction (Figure VE 
in the Data Supplement).
As mentioned above, AAV–VEGF-CC156S gene delivery 
substantially increased lymphangiogenesis in viable LV 
(Figure 1B through 1D), but it did not increase infarct lym-
phangiogenesis as compared with AAV-MI controls (Fig-
ure 2A through 2D). Cardiac whole-mount staining further 
revealed an expanded lymphatic network in the viable LV 
bordering the infarct in AAV–VEGF-CC156S–treated mice 
at 21 days post-MI, including regeneration of straight, 
valved precollector segments reaching towards the base 
of the aorta (Figure 1E). In agreement with potent stim-
ulation of cardiac lymphatic growth in viable LV of AAV–
VEGF-CC156S–treated mice, cardiac expression analyses 
revealed increased levels of lymphatic-selective mark-
ers Lyve1 (lymphatic vessel endothelial receptor 1), Flt4 
(Vegfr3), and podoplanin (Pdpn) at 21 days post-MI as 
compared to AAV-MI controls (Figure 1F). Together, these 
findings indicated that persistent therapeutic stimulation 
of VEGFR3 signaling in the heart sufficed to accelerate 
lymphatic capillary expansion but also to limit MI-induced 
loss of open lymphatic vessels in the viable LV, similar to 
our previous findings with cardiac-targeted lymphangio-
genic protein therapy in rats.26 Furthermore, we found that 
the stimulation of lymphangiogenesis was restricted to the 
heart following AAV-9 VEGF-CC156S gene therapy because 
although transgene expression also occurred in the liver, 
it was not sufficient to stimulate liver lymphangiogenesis 
in the absence of other triggers such as inflammation or 
edema (data not shown). Finally, AAV–VEGF-CC156S gene 
therapy did not influence infarct scar size, heart-to-body 
weight ratio, cardiomyocyte hypertrophy, or cardiac angio-
genesis and arteriolar remodeling as compared to AAV-MI 
controls (Figure VIA through VIG in the Data Supplement).
Therapeutic Lymphangiogenesis Limits Cardiac 
Inflammation and Dysfunction Post-MI in Mice
We next set out to investigate the functional impact of 
therapeutic lymphangiogenesis on cardiac inflamma-
tion in the acute (7 days) and chronic (21 days) phases 
of repair and recovery after MI. We hypothesized that 
expansion of cardiac lymphatics, as induced by AAV–
VEGF-CC156S therapy, would accelerate resolution of 
inflammation by expediting cardiac efflux of proinflam-
matory immune cells.
First, we analyzed the kinetics and profile of car-
diac inflammation in the viable LV bordering the infarct 
in saline-injected MI control mice using immunohisto-
chemistry and flow cytometry. We found that cardiac 
CD68+ macrophage density increased rapidly during 
the first-week post-MI (Figure VIIA and VIID in the Data 
Supplement). These macrophages were initially mostly 
of classical M1 type (negative for CD206, and positive 
for CCR2 [chemokine receptor 2]; Figure VIIB, VIIE, 
VIIG in the Data Supplement). Furthermore, CD3+ total 
T-cell densities peaked already by day 3 in the viable 
LV, with persistent elevation of CD8+ T cells observed at 
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7 days post-MI (Figure VIIC, VIIF, VIIH, VIII in the Data 
Supplement).
Second, we investigated cardiac immune cell popula-
tion dynamics in both the acute and chronic phases post-
MI in our AAV-treated groups. In AAV-MI control mice, 
similar as in saline-treated MI mice, the cardiac levels 
of proinflammatory immune cells, including M1 macro-
phages and CD3+ T cells, were transiently elevated in 
both infarct (Figure 3E through 3G) and viable LV (Fig-
ure 3A and 3B). At 7 days, the cardiac T-lymphocyte 
population included 48±3% CD4+ and 41±2% CD8+ 
cells among all CD3+ T cells in the noninfarcted LV wall 
in AAV-MI controls. In contrast, cardiac-infiltrating Tregs 
were very sparse at all time points analyzed (1.8±0.5 
cells/mm2 observed in infarct at 7 days post-MI, repre-
senting only 2% to 5% of all CD4+ T cells).
Figure 1. Adeno-associated viral (AAV)-VEGF (vascular endothelial growth factor)-CC156S therapy stimulates cardiac 
lymphangiogenesis postmyocardial infarction (MI).
Mice were treated with AAV-hVEGF (human VEGF)-CC156S gene therapy (red circles, n=8), sVEGFR3 (vascular endothelial growth factor 
receptor 3; AAV-sVEGFR3, blue triangles, n=5–7), or AAV-scrambled virus (MI controls, black circles, n=8), and sham-operated mice (white 
circles, n=7–9) served as healthy controls. Cardiac gene expression of lymphangiogenic factors at 21 days post-MI (A). Lymphangiogenesis 
in the viable left ventricular (LV) wall bordering the infarct was evaluated as % proliferating lymphatic vessels (B), lymphatic densities (C), and 
lymphatic area at 7 or 21 days post-MI (D). Examples of light sheet imaging (E, left) of Lyve1+ (lymphatic vessel endothelial receptor 1) cardiac 
lymphatics in healthy mice, in AAV-MI controls, and VEGFC-treated (AAV–VEGF-CC156S) mice at 21 d post-MI. Infarct outlined by white dashed 
lines. Scale bar=1 mm; ×0.8. Confocal imaging (E, right) of viable LV areas in the same samples. Cardiac precollectors indicated by white 
asterisk. Scale bar=50 µm; ×25. Relative cardiac expression of lymphatic-related genes in sham (n=8), MI controls (AAV-scrambled virus, 
n=8), and VEGFC-treated (AAV-hVEGF-CC156S, n=5) at 21 days post-MI (F). Kruskal-Wallis followed by Dunn posthoc test. *P<0.05 vs sham; 
#P<0.05; ##P<0.01; ###P<0.001 vs AAV-MI controls. con indicates control.
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AAV–VEGF-CC156S lymphangiogenic therapy led to a 
substantial reduction in both T-cell and macrophage densi-
ties in the viable LV (Figure 3A and 3B). Importantly, this 
decrease was restricted to M1 proinflammatory macro-
phages, as the numbers of M2-like regenerative macro-
phages did not differ from AAV-MI controls (5±2 versus 
5±1 M2-like cells/mm2 at 21 days). In contrast, in the infarct 
zone, total CD3+ and CD8+ T-cell densities were unaltered 
(Figure 3E through 3G). These data revealed expedited 
resolution of inflammation by expanded and activated car-
diac lymphatics only in the viable LV, but not in the infarct 
zone where lymphatics remain severely altered despite the 
lymphangiogenic therapy (Figure 1E, Figure 2B). In addition 
to lymphatic vessel expansion, AAV–VEGF-CC156S–treated 
mice displayed increased cardiac expression of the LEC-
derived chemokine Ccl21 (Figure 1F), which may mediate 
lymphatic clearance of cardiac-infiltrating T cells, notably 
naive/central memory cells expressing the cognate CCR7 
receptor. Similarly, cardiac Ccl2 levels were also increased, 
whereas Cx3cl1 levels were unaltered (Figure 1). Taken 
together, we found that stimulation of lymphangiogenesis 
with AAV–VEGF-CC156S reduced T-cell densities only in the 
viable LV and not in the infarct where lymphatics remained 
highly dysfunctional and presumably incapable of mediat-
ing immune cell exit.
We next evaluated the functional cardiac impact at 21 
days post-MI by echocardiography. We found that AAV-
MI control mice displayed similar cardiac dysfunction and 
remodeling as MI mice injected with saline (Table 1, Table 
I in the Data Supplement), indicating that AAV gene 
delivery does not adversely affect the functional cardiac 
response to injury.
AAV–VEGF-CC156S therapy improved cardiac function, 
including LV fractional shortening (Figure 3C) and LV 
anterior wall thickening fraction (33±6 versus 21±2%. 
LV anterior wall thickness, P=0.07, Table 1) as compared 
to AAV-MI controls. In contrast, it did not alter LV wall 
thickness or scar maturation (Figure 3D, 3H through 3I). 
This promisingly reveals that selective stimulation of car-
diac lymphangiogenesis, and the associated accelerated 
resolution of cardiac inflammation in the viable LV, suf-
fices to improve cardiac function after MI.
Figure 2. Adeno-associated viral (AAV)-sVEGFR3 (soluble vascular endothelial growth factor receptor 3) therapy inhibits infarct 
lymphangiogenesis postmyocardial infarction (MI).
Mice were treated with AAV-hVEGF (human VEGF)-CC156S gene therapy (red circles, n=8), sVEGFR3 (AAV-sVEGFR3, blue triangles, 
n=5–7), or AAV-scrambled virus (MI controls, black circles, n=8), and sham-operated mice (white circle, n=7–9) served as healthy controls. 
Lymphangiogenesis in the infarct scar was evaluated as % proliferating lymphatic vessels (A), open lymphatic densities (B), and lymphatic area 
at 7 or 21 days post-MI (C). Examples (D) at 21 days post-MI of infarct zone left ventricular lymphatics (Lyve1 [lymphatic vessel endothelial 
receptor 1], red), macrophages (F4-80, gray), and cell nuclei (DAPI, blue); ×20 magnification, scale bar=50 µm. Note LYVE1-expressing 
macrophages close to lymphatic vessels. con indicates control.
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Soluble VEGFR3 Inhibits Infarct 
Lymphangiogenesis Post-MI in Mice
To investigate the impact of the endogenous lym-
phangiogenic response post-MI, we next applied a 
VEGF-C/VEGF-D trap (sVEGFR3), delivered by an 
AAV vector, to block VEGF-C/-D signaling in the 
heart. Due to the low endogenous level of VEGF-C 
and VEGF-D expression and poor lymphangiogenesis 
in mice post-MI, notably in the viable LV (Figure 1A 
and 1B), AAV-sVEGFR3 inhibition of lymphatic pro-
liferation did not reach significance (AAV-sVEGFR3: 
1.4±1.0 versus AAV-MI control: 8.0±4.0% proliferat-
ing vessels in the infarct at 7 days post-MI, P=0.12, 
Figure 2A) nor did it reduce total lymphatic densi-
ties (AAV-sVEGFR3: 27±15 versus AAV-MI control: 
Figure 3. Adeno-associated viral (AAV) delivery of VEGF (vascular endothelial growth factor)-CC156S reduces cardiac 
inflammation and improves cardiac function, while AAV-sVEGFR3 (soluble VEGF receptor 3) therapy reduces infarct scar T-cell 
levels and wall thinning leading to improved cardiac function in mice postmyocardial infarction (MI).
Cardiac densities in the viable left ventricular (LV) of CD3+ T cells (A) and M1 pro-inflammatory macrophages (CD68+/CD206− cells), (B) were 
determined by immunohistochemistry in MI controls (AAV-scramble, black circles, n=8), and VEGFC (AAV–VEGF-CC156S, red circles, n=7–8) 
or sVEGFR3 (AAV-sVEGFR3, blue triangles, n=5–7) treated mice at 7 and 21 d post-MI. Healthy sham levels (n=7–9) are indicated by white 
circles / bars. Cardiac function and remodeling were analyzed by echocardiography at 21 days post-MI to determine LV fractional shortening 
(C) and LV anterior wall thickness in end-systole (AWT ES, D). Infarct densities of CD3+ total T cells (E) and CD8+ T-cell subpopulation (F). 
Examples of CD8+ T-cell density in the infarct at 7 d post-MI (G). CD3 (red), CD8 (green), DAPI (blue), ×20 magnification, scale bar=50 µm. 
Infarct scar remodeling evaluated in Sirius red-stained histological sections as absolute infarct area (H) at 21 days post-MI in MI controls 
(AAV-scramble, n=8), VEGFC-(AAV-hVEGF-CC156S, n=7–8) and sVEGFR3-(AAV-sVEGFR3, n=5–7) treated mice. Examples of infarct scar 
remodeling. Scale bar=1 mm (I). LV hypertrophy/dilatation index was calculated from echocardiographic parameters at 21 days post-MI (J). 
Kruskal-Wallis, Dunn posthoc test. *P<0.05; **P<0.01; ***P<0.001 vs sham; #P<0.05; ##P<0.01 vs MI control. con indicates control.
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58±12 vessels/mm2 in the infarct at 21 days post-MI, 
P=0.12). However, open lymphatic vessel density and 
total lymphatic area in the infarct zone was markedly 
reduced at 21 days (Figure 2B through 2D), reveal-
ing a key role for endogenous VEGF-C and VEGF-D 
in limiting MI-induced rarefaction of open lymphatic 
vessels in the infarct. Although AAV-sVEGFR3 did not 
influence infarct scar size, heart-to-body weight ratio, 
cardiomyocyte hypertrophy, or angiogenesis (Figure 
VIA through VID in the Data Supplement), arteriogen-
esis was reduced in the viable LV at 21 days post-
MI, as compared to AAV-MI controls, although arterial 
sizes tended to be increased (Figure VIE through VIG 
in the Data Supplement). This indirectly suggests that 
endogenous VEGF-C and VEGF-D ligands may par-
ticipate in regulation of arteriogenesis post-MI acting 
via VEGFR2 expressed by blood vascular endothelial 
cells, as previously published,39 as we did not detect 
VEGFR3 expression in cardiac blood vessels post-MI 
(Figure II in the Data Supplement).
Soluble VEGFR3 Limits Infarct T-Cell Levels 
and Reduces Deleterious Cardiac Remodeling
Investigating next the functional cardiac impact of the 
VEGF-C/VEGF-D trap, we expected that the treat-
ment would not influence cardiac immune cell levels 
nor cardiac function post-MI, given its limited effects 
on cardiac lymphangiogenesis beyond the infarct. 
Indeed, AAV-sVEGFR3 treatment, which, as mentioned 
above, did not reduce total lymphatic density as com-
pared to AAV-MI controls, did not aggravate cardiac 
inflammation in the viable LV and both T-cell and M1 
macrophage densities were found to be unaltered 
(Figure 3A and 3B). Surprisingly, at 7 days post-MI 
in the infarct, where AAV-sVEGFR3 aggravated MI-
induced loss of open lymphatic vessels (Figure 2C), 
we found a marked reduction of cardiac T-cell levels, 
both total CD3+ T-cell and CD8+ T-cell subpopulation 
(Figure 3E through 3G), as compared to AAV-MI con-
trols. A similar effect of the VEGF-C/VEGF-D trap on 
limiting cardiac T-cell infiltration has been described 
previously in a mouse model of allograft transplanta-
tion,13 although its mechanistic explanation awaits fur-
ther studies.
Echocardiographic analyses revealed unexpectedly 
that sVEGFR3 treatment improved cardiac function 
as compared to AAV-MI controls. Indeed, both frac-
tional shortening and LV wall thickness (Figure 3C and 
3D), notably of the anterior myocardial segment, were 
improved. Given that LV cardiomyocyte hypertrophy 
was not increased (Figure VIC in the Data Supple-
ment), this prevention of MI-induced LV wall thinning 
observed in sVEGFR3-treated mice likely reflected 
increased scar thickness/strength linked to reduced 
infarct T-cell levels. Indeed, previous studies have 
shown improved infarct healing in the absence of T 
cells.40 In support of this mechanism, infarct thinning 
was found to be reduced, and scar area increased at 
21 days post-MI by sVEGFR3 treatment (Figure 3H 
and 3I). As a direct hemodynamic consequence of 
reduced wall thinning, cardiac hypertrophy-to-LV dil-
atation index was improved (Figure 3J), explaining 
Table 1. Functional Cardiac Evaluation at 21 Days Post-MI in Mouse AAV Study
Sham AAV-Scr AAV–VEGF-CC156S AAV-sVEGFR3
Mean±SEM Mean±SEM vs Sham Mean±SEM vs AAV-Scr Mean±SEM vs AAV-Scr
AWT ED, mm 0.81±0.03 0.52±0.04 P<0.01 0.54±0.04 n.s 0.65±0.06 n.s
AWT ES, mm 1.21±0.05 0.63±0.05 P<0.01 0.71±0.05 n.s 0.92±0.10 P<0.05
AW FT, % 49±6 21±2 P<0.05 33±6 P=0.07 42±7 P<0.05
PWT ED, mm 0.96±0.07 0.84±0.09 n.s 0.84±0.08 n.s 1.13±0.13 n.s
PW ES, mm 1.24±0.05 1.05±0.13 n.s 1.00±0.11 n.s 1.34±0.16 n.s
PW FT, % 31±6 24±4 n.s 17±5 n.s 18±5 n.s
LVEDD, mm 2.7±0.2 5.4±0.1 P<0.05 5.4±0.3 n.s 5.1±0.4 n.s
LVESD, mm 1.3±0.2 4.9±0.1 P<0.05 4.4±0.3 n.s 4.2±0.4 n.s
FS, % 51±4 10±1 P<0.01 19±1 P<0.01 17±2 P<0.05
VTI, cm 3.0±0.1 2.2±0.1 P<0.01 2.1±0.1 n.s 2.4±0.2 n.s
HR, bpm 422±9 424±4 n.s 438±18 n.s 423±16 n.s
SV, mL/beat 0.08±0.00 0.06±0.00 P<0.01 0.06±0.00 n.s 0.07±0.00 n.s
CO, mL/min 35±1 26±2 P<0.01 25±1 n.s 28±2 n.s
CI, mL/(min·g) 1.7±0.1 1.2±0.1 P<0.01 1.2±0.1 n.s 1.3±0.1 n.s
Multiple comparisons by Kruskal Wallis analysis followed by Dunn posthoc. AAV indicates adeno-associated viral; AW FT, anterior wall fractional thickening; AWT ED, 
end-diastolic anterior wall thickness; AWT ES, end-systolic anterior wall thickness; CI, cardiac index; CO, cardiac output; FS, LV fractional shortening; HR, heart rate; LV, 
left ventricular; LVEDD, LV end-diastolic diameter; LVESD, LV end-systolic diameter; MI, myocardial infarction; n.s, nonsignificant; PW FT, posterior wall fractional thick-
ening; PWT ED, end-diastolic posterior wall thickness; PWT ES, end-systolic posterior wall thickness; Scr, scrambled sequence; SV, stroke volume; sVEGFR3, soluble 
vascular endothelial growth factor receptor 3; and VTI, velocity-time integral.
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the improvement of cardiac function observed in 
sVEGFR3-treated mice.
To confirm the beneficial effects of sVEGFR3 
on cardiac function post-MI, we extended our stud-
ies to a rat MI model, again using AAV gene deliv-
ery of either sVEGFR3 or a scrambled sequence in 
MI controls. We again found that sVEGFR3 reduced 
lymphangiogenesis in the infarct, but had no effect 
on angiogenesis (Figure 4A through 4C). Serial echo-
cardiography revealed that cardiac function, notably 
fractional shortening, was improved at 28 days post-
MI (Figure 4D). Furthermore, sVEGFR3 reduced LV 
dilation (Figure 4E) and interventricular septal wall 
thinning (Figure 4F) and, as a consequence, improved 
cardiac hypertrophy-to-LV dilatation index, as com-
pared to AAV-MI controls (Figure 4G, Table 2). This 
suggested, similar to our findings in mice, that cardiac 
function was improved by sVEGFR3 treatment due to 
reduced LV wall thinning linked to delayed infarct scar 
remodeling. Taken together, our studies suggest that 
sVEGFR3 treatment reduced infarct thinning by limit-
ing cardiac infiltration of T cells. This led to prevention 
of deleterious LV wall remodeling post-MI resulting in 
improved cardiac function.
Figure 4. Adeno-associated viral (AAV)-sVEGFR3 (soluble vascular endothelial growth factor receptor 3) therapy suppresses 
infarct lymphangiogenesis and improves cardiac function and remodeling in rats postmyocardial infarction (MI).
Lymphatic remodeling was investigated in cardiac sections from MI controls (AAV-scramble, black circles, n=8) and sVEGFR3-treated (AAV-
sVEGFR3, blue triangles, n=9) rats. Examples of blood vessels and lymphatics in the infarct zone at 28 d post-MI (A): middle panel: lymphatics 
(VEGFR3, red), and blood vessels (RECA1, green); bottom panel: lymphatics (Lyve1 [lymphatic vessel endothelial receptor 1], green; 
Prox1 [homeobox gene homologue Drosophilia prospero gene], red). ×20, scale bar=50 µm. White dashed lines outline infarct epicardium. 
Quantification of VEGFR3+ lymphatic area (B) and RECA1+ blood vascular area (C) in the infarct at 28 days post-MI. Comparison by Student 
2-tailed t test: ***P<0.001 vs MI control. Cardiac function was investigated by serial echocardiography in healthy sham rats (open circles, 
n=4), MI controls (AAV-scramble, black circles, n=13), and sVEGFR3-treated (AAV-sVEGFR3, blue triangles, n=10) MI rats. Left ventricular 
(LV) fractional shortening (D), end-systolic diameter (ESD, E), systolic interventricular septal wall thickness (IVSTs, F) were measured, and 
LV hypertrophy/dilatation index (G) calculated. Two-way ANOVA, followed by Bonferroni posthoc: *P<0.05; **P<0.01; ***P<0.001 vs sham; 
#P<0.05, ##P<0.01 vs MI control. RECA indicates rat endothelial cell antigen.
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Cardiac-Infiltrating CD4+ and CD8+ T Cells 
Suppress Lymphangiogenesis Post-MI
We next sought to investigate the cellular mechanisms 
orchestrating the cardiac lymphatic response to ischemic 
injury. Previous studies have revealed that immune cells 
contribute to regulation of lymphangiogenesis in many 
tissues.7,8,41 However, whether cardiac-infiltrating immune 
cells influence lymphangiogenesis post-MI has not been 
previously investigated. As mentioned above, our data in 
AAV-MI controls indicated that macrophages present in 
the infarct at day 7 may have contributed to scar lym-
phangiogenesis by locally producing VEGF-C (Figure 
IVD in the Data Supplement). We next turned our atten-
tion to T lymphocytes, given their well-documented acute 
deleterious effects on infarct remodeling, including both 
direct and indirect effects on cardiomyocytes, fibroblast, 
and vascular cells.27,42,43 We hypothesized that CD4+ 
helper or CD8+ cytotoxic T cells additionally may con-
tribute to the poor endogenous cardiac lymphangiogenic 
response observed acutely post-MI in our mouse model. 
To prevent T-cell mobilization and cardiac entry after MI, 
we treated mice with an S1P (sphingosine-1-phosphate) 
receptor agonist, Fingolimod, as described.33 Due to the 
angiogenic and lymphangiogenic effects associated with 
chronic S1P stimulation,44,45 we restricted treatment to 
the first 48 hours following MI to selectively target acute-
phase cardiac T-cell recruitment. We found, as expected, 
that Fingolimod potently reduced circulating and cardiac 
T-cell levels (Figure 5A through 5C, Figure VIIIA in the 
Data Supplement). However, by 21 days post-MI, cardiac 
T cells in the viable LV of control MI mice returned to 
healthy sham levels, and no difference was observed in 
the Fingolimod group at this later time point. Similarly, 
in the infarct, where MI controls displayed persistently 
elevated T-cell levels, acute-phase Fingolimod treatment 
did not suppress chronic phase T-cell levels. Interestingly, 
Fingolimod-induced prevention of cardiac T-cell recruit-
ment at 3 days post-MI led to a significant reduction of 
M1 proinflammatory macrophage densities in the viable 
LV at 7 days post-MI (Figure 5D).
Prevention of cardiac T-cell recruitment by Fingolimod 
strikingly reduced MI-induced lymphatic rarefaction, with 
increased density of total lymphatics (Figure 5E) as well 
as open lymphatics observed in the viable LV (Figure 5F 
and 5G), as compared to MI controls. Although cardiac 
LEC proliferation rates were not increased by Fingolimod 
(Fingolimod: 15.1±2.3 versus MI controls: 13.2±1.6% 
proliferating lymphatics at 3 days), cardiac lymphatic 
density at 7 days post-MI was inversely correlated with 
cardiac T-cell density (Figure VIIIC in the Data Supple-
ment). Remarkably, the results observed at 7 days in the 
viable LV of Fingolimod-treated mice (Figure 5E and 5F) 
closely mirror our findings with the AAV–VEGF-CC156S 
therapy (Figure 1C, Figure VC in the Data Supplement), 
indicating that cardiac-recruited T cells mediate adverse 
lymphatic remodeling and rarefaction after MI. However, 
different from lymphangiogenic gene therapy, the lym-
phatic density was reduced by 21 days post-MI in the 
Fingolimod-treated group (Figure 5E and 5F), although 
T-cell levels at this later stage were no longer elevated 
in the viable LV (Figure 5C). This indicates that beyond 
stimulation of initial LEC growth or survival post-MI, the 
maintenance of newly formed lymphatic vessels requires 
prolonged expression of lymphangiogenic factors. This 
may explain why AAV therapy, but not adenoviral therapy, 
induced cardiac lymphatic expansion post-MI.
In the infarct, Fingolimod-induced acute suppression 
of T cells similarly increased lymphatic density by 7 days 
(Figure VIIIB in the Data Supplement). However, the 
Table 2. Functional Evaluation by Echocardiography at 7 and 28 Days Post-MI in Rat AAV Study
Sham AAV-scr AAV-sVEGFR3
7 d 28 d 7 d vs Sham 28 d vs Sham 7 d vs AAV-Scr 28 d vs AAV-Scr
IVS ED, mm 1.3±0.1 1.3±0.1 1.3±0.1 n.s. 1.2±0.1 n.s. 1.5±0.1 P<0.01 1.5±0.1 P<0.001
IVS ES, mm 3.0±0.1 3.1±0.1 2.2±0.2 n.s. 2.3±0.2 P<0.05 2.3±0.2 P<0.05 2.3±0.2 P<0.05
IVS FT, % 128±9 145±15 74±9 P<0.05 77±12 P<0.001 67±10 n.s. 90±11 n.s.
PWT ED, mm 1.5±0.1 1.6±0.1 1.7±0.1 n.s. 1.8±0.1 n.s. 1.7±0.1 n.s. 1.9±0.1 n.s.
PW ES, mm 3.0±0.1 3.1±0.2 2.7±0.1 n.s. 2.9±0.1 n.s. 3.0±0.1 n.s. 3.2±0.1 P<0.05
PW FT, % 100±12 100±13 57±6 P<0.001 60±6 P<0.01 78±7 P<0.05 73±7 n.s.
LVEDD, mm 6.8±0.4 7.2±0.4 7.3±0.2 n.s. 8.1±0.3 n.s. 7.1±0.1 n.s. 7.6±0.2 n.s.
LVESD, mm 2.5±0.3 2.7±0.1 4.3±0.3 P<0.01 4.9±0.4 P<0.000 3.8±0.3 n.s. 3.7±0.3 P<0.01
FS, % 63±2 63±2 42±3 P<0.001 40±4 P<0.001 47±3 n.s. 52±3 P<0.05
SV, mL/beat 0.69±0.09 0.84±0.13 0.66±0.03 n.s. 0.83±0.05 n.s. 0.67±0.03 n.s. 0.84±0.05 n.s.
Multiple comparisons by 2-way ANOVA followed by Bonferroni posthoc. AAV indicates adeno-associated viral; FS, LV fractional shortening; IVS ED, end-diastolic 
interventricular septum wall thickness; IVS ES, end-systolic interventricular septum wall thickness; IVS FT, interventricular septum fractional thickening; LV, left ventricu-
lar; LVEDD, LV end-diastolic diameter; LVESD, LV end-systolic diameter; MI, myocardial infarction; n.s, nonsignificant; PW FT, posterior wall fractional thickening; PWT 
ED, end-diastolic posterior wall thickness; PWT ES, end-systolic posterior wall thickness; Scr, scrambled sequence; SV, stroke volume; and sVEGFR3, soluble vascular 
endothelial growth factor receptor 3.
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MI-induced early slimming and rarefaction of open lym-
phatic vessels was not prevented (Figure VIIID through 
VIIIF in the Data Supplement), likely due to incomplete 
inhibition of T-cell invasion by Fingolimod in the infarct 
(Figure VIIIA in the Data Supplement). Surprisingly, by 
21 days post-MI, both total lymphatic density and open 
vessel density were increased in the infarct in Fingoli-
mod-treated mice, as compared to MI controls, despite 
the return of T cells to control MI levels. This indicates 
that only T-cell activity in the acute post-MI phase lim-
its lymphangiogenesis. In contrast, blood vessel rar-
efaction, observed during the first-week post-MI, was 
not significantly altered by Fingolimod (Figure VIIIH in 
the Data Supplement). Furthermore, in agreement with 
previous findings,46 at 21 days post-MI, although infarct 
size was not altered (Figure VIIIG in the Data Supple-
ment), cardiac function and remodeling were improved 
in Fingolimod-treated mice as compared to MI controls 
Figure 5. Cardiac-infiltrating T cells suppress lymphangiogenesis in mice postmyocardial infarction (MI).
Circulating T-cell levels (A and B) were determined by flow cytometry in saline-injected MI controls (black circles, n=4–5) and Fingolimod-
treated wild-type (wt) MI mice (yellow triangles, n=4–5) at 3 and 7 days post-MI and healthy sham mice (white circles, n=4). Cardiac 
sections were analyzed to determine densities of CD3+ total T cells (C), M1 proinflammatory macrophages (D), lymphatic vessels (E), and 
open lymphatic vessels (F) in the viable left ventricular (LV) of saline-injected MI controls (black circles, n=4–13) and Fingolimod-treated MI 
mice (yellow triangles, n=7–9) at 3, 7 and 21 days post-MI. Healthy sham levels (n=5–10) indicated by white circle. One-way ANOVA, Dunn 
posthoc test. *P<0.05; **P<0.01; ***P<0.001 vs sham; #P<0.05; ##P<0.01 vs MI controls. Examples of cardiac lymphatics (Lyve1 [lymphatic 
vessel endothelial receptor 1], red) in the viable LV at 7 days post-MI (G). ×20, scale bar=50 µm. Note peri-lymphatic macrophages (CD68, 
green). Analysis of lymphatic remodeling in wt (black, n=7) vs MHC (major histocompatibility complex) IIΔ/Δ CD4+ T cell-deficient (yellow, n=6) 
mice at 7 days post-MI assessed as densities of total lymphatic vessel (H) and open lymphatic vessels (I and J) in the infarct zone. Kruskal-
Wallis followed by Dunn posthoc test. #P<0.05 vs wt MI controls. Examples of Lyve1+ (green) lymphatics and CD31+ blood vessels (red) in 
the infarct zone at 7 days post-MI (J). ×10, scale bar=50 µm. APC indicates antigen-presenting cell.
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(Figure VIIII through VIIIK and Table I in the Data Supple-
ment). Indeed, Fingolimod treatment, similar to sVEGFR3 
treatment, reduced LV wall thinning and improved car-
diac hypertrophy-to-LV dilatation index (Table I and Fig-
ure VIIIK in the Data Supplement). Taken together, our 
data demonstrate that T cells recruited to the heart in 
the acute-phase post-MI contribute to lymphatic loss and 
deleterious remodeling after MI.
To determine which subset of T cells was responsible 
for the deleterious impact on cardiac lymphatics post-MI, 
we next investigated lymphatic remodeling in MHCIIΔ/Δ 
mice that lack CD4+ T cells. We found that infarct sizes 
were similar between wild-type mice and MHCIIΔ/Δ 
mice at 7 days post-MI (Figure IXA in the Data Supple-
ment). Cardiac lymphatic densities and total lymphatic 
areas were similar in CD4+-deficient mice as compared 
to wild-type mice both at baseline (before MI) and at 7 
days post-MI (Figure 5H, Figure IXB in the Data Supple-
ment). In contrast, open lymphatic vessel density in the 
infarct was significantly increased at 7 days post-MI in 
mice lacking CD4+ T cells (Figure 5I and 5J), consistent 
with the data from Fingolimod-treated mice. Further-
more, in the absence of cardiac-infiltrating CD4+ T cells 
in MHCIIΔ/Δ mice, flow cytometric evaluation revealed 
increased cardiac macrophage density but decreased 
levels of proinflammatory M1 (CD206−/ CD86+) mac-
rophages at 7 days post-MI (Figure IXC and IXD in the 
Data Supplement), similar as our findings with Fingoli-
mod (Figure 5D).
To confirm the specific involvement of cardiac-infiltrat-
ing T cells, we next applied in vivo depleting antibodies to 
acutely block CD4+ or CD8+ T-cell subsets immediately 
post-MI. Additionally, given that IFN (interferon)-γ has 
been proposed as a major T-cell–derived lymphangio-
genic inhibitor,8,47 we evaluated the impact of neutralizing 
antibodies against this Th1 cytokine. Flow cytometry at 
2 and 8 days post-MI confirmed selective knockdown 
of circulating CD4+ or CD8+ T cells (Figure 6A and 6B). 
Immunohistochemistry of cardiac sections at 8 days 
post-MI similarly confirmed selective depletion of car-
diac T-cell subsets (Figure 6C and 6D). We found that 
CD4+ or CD8+ depletion prevented lymphatic rarefac-
tion post-MI (Figure 6E through 6G), although it did not 
reduce lymphatic precollector slimming (Figure XD in the 
Data Supplement). Interestingly, whereas neutralization 
of IFNγ did not alter circulating or cardiac T- or B-cell 
levels (Figure 6A through 6C, Figure XA and XB in the 
Data Supplement), it partially blocked MI-induced delete-
rious lymphatic remodeling, including loss of open lym-
phatic vessels in the heart (Figure XC and XE in the Data 
Supplement). In conclusion, our data reveal that cardiac-
infiltrating CD4+ and CD8+ T cells exert potent deleteri-
ous effects on cardiac lymphatics and contribute, in part, 
through IFNγ, to rarefaction of both lymphatic capillaries 
and precollectors in the acute-phase post-MI.
DISCUSSION
In this study, we demonstrated that therapeutic stimu-
lation of lymphatic vessel growth in the heart required 
sustained elevated expression of lymphangiogenic 
growth factors, as achieved by AAV but not adenoviral 
gene therapy. Moreover, although we previously dem-
onstrated that lymphangiogenesis may be induced by 
intramyocardial sustained-release of VEGF-C protein, 
we found that systemic delivery of recombinant human 
VEGF-CC156S protein, as proposed recently,
25,38 was inef-
ficient to increase cardiac lymphangiogenesis. Indeed, 
although our study revealed no increase in either plasma 
VEGF-C levels or lymphatic proliferation in the heart 
in response to repeated intraperitoneal injections of 
VEGF-CC156S protein, the previous studies, based on the 
same approach, notably did not provide any evidence of 
increased circulating or cardiac VEGF-C levels.25,38 Con-
sequently, our data support the concept of strict time- 
and dose-dependence of VEGF-C delivery to achieve 
therapeutic lymphangiogenesis in the heart. Promisingly, 
our study revealed that therapeutic expansion of lym-
phatic vessels accelerated resolution of cardiac inflam-
mation with reduction of both cardiac T lymphocytes 
and M1 proinflammatory macrophages in the viable LV. 
This selective improvement of immune cell clearance, 
without modification of angiogenesis or cardiomyocyte 
hypertrophy, significantly reduced cardiac dysfunction. 
To further advance our understanding of how cardiac 
lymphangiogenesis is regulated after MI, with the aim 
to develop better therapies, future studies may benefit 
from assessment not only of VEGF-C/ VEGF-D but also 
of the molecular partners essential for their proteolytic 
processing, CCBE1 (collagen- and calcium-binding EGF 
domains 1) and ADAMTS3 (a disintegrin and metallopro-
teinase with a thrombospondin type I motif 3).48
Our findings of the cardiac functional benefit with 
sVEGFR3 treatment in both mouse and rat MI models 
were completely unexpected. The absence of aggrava-
tion of cardiac inflammation was likely due to the low 
endogenous level of lymphangiogenesis observed in the 
viable LV post-MI, leading to limited functional impact of 
antilymphangiogenic therapy. However, in both mice and 
rats, we found reduced LV wall thinning with sVEGFR3 
due to delayed infarct scar remodeling. These beneficial 
functional cardiac effects of sVEGFR3 were observed in 
female mice. Interestingly, a recent study also investigat-
ing sVEGFR3 treatment in male mice reported increased 
post-MI mortality linked to cardiac rupture.49 This appar-
ent discrepancy with our findings may be explained by the 
sex-dependence of extracellular matrix remodeling post-
MI, with weaker scars formed in male mice.50 It is likely 
that the sVEGFR3-induced delay in infarct maturation, 
due to prevention of T-cell infiltration, is beneficial only in 
female mice, as in males, the scar will rupture if not rap-
idly matured. Importantly, we observed functional cardiac 
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benefit of sVEGFR3 treatment in male rats, which have 
thicker scars than mice. This indicates that both sex and 
species-differences in post-MI wall strength may influ-
ence the risk/benefit of acute-phase T-cell–modulating 
therapies. This issue will require further mechanistic stud-
ies. Taken together, our data revealed that whereas stim-
ulation of cardiac lymphangiogenesis with VEGF-CC156S 
was beneficial after MI, due to accelerated resolution 
Figure 6. Depletion of CD4 and CD8, but not NKT, T-cell subpopulations prevents rarefaction of cardiac lymphatics acutely 
postmyocardial infarction (MI).
Assessment by flow cytometry at 8 days post-MI of circulating T-cell populations (A and B) in control MI mice (black, n=2), CD4-depleted 
mice (yellow, n=6), CD8-depleted mice (blue, n=6), and mice treated with an IFN (interferon) γ–neutralizing antibody (red, n=6). Evaluation 
by immunohistochemistry of viable left ventricular (LV) at 8 days post-MI of CD4+ and CD8+ cardiac T-cell densities (C) and total lymphatic 
density (E) and lymphatic area (F) in healthy sham mice (white, n=3–5) control MI mice (black, n=10), CD4-depleted mice (yellow, n=6), CD8-
depleted mice (blue, n=6), and anti-IFNγ–treated mice (red, n=7). Examples of cardiac T-cell densities (D) and lymphatic densities (G) in viable 
LV at 8 days post-MI. CD4+ cells indicated by arrow, CD8+ cells by arrowhead, and open lymphatics indicated by asterisk. ×20, scale bar=50 
µm. Kruskal-Wallis followed by Dunn posthoc test. *P<0.05; ***P<0.001 vs sham; #P<0.05; ###P<0.001 vs MI controls.
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of inflammation in the viable LV wall, treatment with the 
VEGF-C/VEGF-D trap also attenuated cardiac remod-
eling due to reduced infarct thinning by suppression of 
recruitment/expansion/activation of T cells in the infarct. 
These lymphangiogenesis-independent immunomodula-
tory effects of sVEGFR3 remain to be further explored. 
However, the beneficial effects previously reported with 
sVEGFR3 therapy in another model of cardiac inflamma-
tion are noteworthy in this context: in a mouse cardiac 
allograft model adenoviral delivery of sVEGFR3 reduced 
cardiac CD8+ T-cell levels.13 This was proposed to be 
linked to decreased cardiac-derived DC homing to the 
spleen, due to reduced cardiac lymphatic expression 
of Ccl21, a major lymphatic chemokine for DCs and T 
cells. In addition, it is possible that endogenous VEGF-C 
and VEGF-D may directly influence cardiac recruitment, 
maturation, and activation of cardiac DCs that express 
both VEGFR2 and VEGFR3.51 In agreement, our prelimi-
nary data indicate significantly reduced mature CD103+ 
CD11c+ DC levels in the heart of sVEGFR3-treated mice 
as compared to AAV-MI controls (sVEGFR3: 18±5 ver-
sus AAV-MI control: 64±19 mature DCs/mm2, P<0.01). 
This suggests that treatment with sVEGFR3 may have 
reduced antigen presentation by cardiac DCs post-MI, 
which would limit recruitment or expansion of T cells in 
the infarct. However, increased cardiac DCs levels in the 
viable LV has been proposed to protect the remodeling 
postischemic heart by limiting M1 proinflammatory mac-
rophage recruitment, inducing a beneficial inflammatory-
to-reparative macrophage shift but also by stimulating 
Treg expansion in cardiac-draining lymph nodes. Of note, 
this mechanism has been proposed to be crucial for 
maintenance of lymphocyte tolerance to self-antigens 
following cardiac injury.52–54 Future studies are needed 
to address the potential impact of lymphangiogenesis on 
cardiac immune tolerance after injury.
Finally, in this study, we uncovered a dominant-nega-
tive role of cardiac-infiltrating T cells, both CD4+ helper 
and CD8+ cytotoxic T cells, on the endogenous cardiac 
lymphangiogenic response acutely post-MI. There are 
many previous reports demonstrating the deleterious 
short- and long-term cardiac effects of T cells, especially 
CD4+ helper cells, on cardiomyocytes, macrophages, and 
fibroblasts.27,42,43 Our data revealed that, in addition, infil-
trating CD4+ and CD8+ T cells reduce cardiac lymphatic 
vessel survival acutely post-MI, in part via IFNγ secre-
tion, rendering the vessels less responsive to endoge-
nous lymphangiogenic stimuli. A similar direct negative 
impact of CD4+ T cells on lymphatics has been described 
in both inflamed skin and lymph nodes.8,41 However, it 
is noteworthy that cardiac lymphatic slimming (reduced 
lymphatic diameters) was not influenced by Fingolimod 
or IFNγ neutralization, nor by AAV–VEGF-CC156S therapy 
or sVEGFR3 treatment, suggesting involvement of fac-
tors other than T-cell–derived cytokines or the VEGF-C/
VEGF-D/VEGFR3 axis.55 Interestingly, adrenomedullin 
was recently shown to increase vessel diameters in 
female mice post-MI.56 Additionally, it has been reported 
that apelin-deficient male mice display increased endog-
enous lymphangiogenesis post-MI, potentially linked to 
elevated cardiac recruitment of VEGF-C-secreting B 
cells.57 Conversely, apelin overexpression by gene ther-
apy limited cardiac inflammation (macrophage density 
and IL [interleukin]-1β levels) post-MI and reduced lym-
phangiogenic responses. Hence inflammation may both 
drive and oppose cardiac lymphangiogenesis. The tipping 
point remains to be determined and may relate to local 
T- and B-cell balance in the heart, similar as suggested 
for remodeling lymph nodes.7,8
A key weakness of our study is that we opted for a 
pretreatment approach with the AAV gene therapy, with 
the aim to achieve similar post-MI acute-phase expres-
sion kinetics of VEGF-CC156S as with adenoviral gene 
therapy to compare these treatments. It thus remains to 
be determined whether AAV-mediated therapeutic gene 
delivery after MI will be equally efficient to stimulate lym-
phatic repair, reduce cardiac inflammation, and improve 
cardiac function. Given that our AAV therapy led to long-
term growth factor delivery, it is likely that this approach 
will be suitable to stimulate cardiac lymphangiogen-
esis also when administered post-MI. Moreover, it will 
be important to assess whether the chronic, low-grade 
inflammation that occurs months after MI in patients 
prone to heart failure development is similarly amenable 
to improvement by lymphangiogenic therapy. Further-
more, in our model, there was no significant fibrosis in 
the viable LV at 21 days post-MI, and it thus remains to 
be determined whether lymphangiogenic gene therapy 
may reduce interstitial cardiac fibrosis post-MI similar, 
as we reported previously in rats. Finally, the effects on 
cardiac remodeling and function of combined stimulation 
of cardiac angiogenesis and lymphangiogenesis post-MI 
remain to be investigated.
Taken together, our findings revealed that cardiac 
inflammation and lymphangiogenic responses are closely 
interconnected. We propose that while therapeutic stim-
ulation of lymphatic remodeling by gene therapy may 
provide a novel approach to limit cardiac inflammation in 
cardiovascular diseases, T-cell–targeted therapy, includ-
ing anti-IFNγ treatment,58 may act in part by enhancing 
endogenous lymphangiogenic responses post-MI lead-
ing to improved lymphatic drainage with accelerated car-
diac fluid and immune cell clearance, both essential for 
optimal cardiac functional recovery and repair.
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